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Open access under the ElArtesunate is a derivate of artemisinin that is both an antimalarial agent and acts cytotoxically on tumor
cells. Despite its therapeutic use, its in vivo genotoxic potential has still not been evaluated. This study,
therefore, was an investigation into the effects of a single oral administration of artesunate with an
in vivo comet assay that analyzed leukocytes from peripheral blood and liver cells, and a micronucleus
(MN) assay of bone marrow cells from male Swiss mice. The artesunate was administered by oral gavage
at doses of 5, 50 and 100 mg/kg. Cytotoxicity was assessed by scoring 200 consecutive polychromatic
(PCE) and normochromatic (NCE) erythrocytes (PCE/NCE ratio). The results demonstrate that artesunate
induced signiﬁcant DNA damage only in liver cells and that high doses of artesunate caused an increase in
the mean number of micronucleated polychromatic erythrocytes (MNPCE). Under our experimental con-
ditions, artesunate showed weak genotoxic effects at low doses and clastogenic effects at high doses. The
PCE/NCE ratio indicated no cytotoxicity. The data obtained suggest caution about either continuous or
high-dose use of artesunate by humans.
 2011 Elsevier Ltd. Open access under the Elsevier OA license. 1. Introduction The combination of oral artesunate and meﬂoquine isMalaria is the most devastating endemic tropical disease in the
world, with between 300 and 500 million clinical cases and almost
three million deaths every year. Most of these deaths are caused by
infection with Plasmodium falciparum, the most harmful species of
malaria parasite (WHO, 2001). The main active principle of the
Artemisia annua plant is known as artemisinin (Klayman, 1985).
Artemisinin and its derivatives, such as artesunate, stand out
among the chemotherapy medicine available for the treatment
and chemoprophylaxis of malaria because this anti-malarial med-
icine presents no clinically relevant resistance to plasmodium
(Meshnick et al., 1996; Dhingra et al., 2000; Olliaro, 2001). Arte-
misinin has been chemically modiﬁed to produce derivatives such
as: sodium artesunate, artemether, arteether, dihydroartemisinin,
and artelinic acid. These compounds have been formulated for oral,
rectal, and parenteral administration. Combinations of these med-
icines have presented fast antimalarial activity and an absence of
clinically important resistance (Woodrow et al., 2005). Artesunate
is the most versatile of these derivatives, because it is easily solu-
ble in water, which has facilitated the development of oral and rec-
tal formulas, and thus is often used both in monotherapy and
combined with other drugs (WHO, 2001; Angus et al., 2002).fax: +55 21 14 34021302.
.L. Maistro).
sevier OA license. commonly used to treat malaria in Southeast Asia. The addition
of artesunate accelerates the therapeutic response, reduces recru-
descence rates and transmissibility, prevents the occurrence of
resistance, increases patient compliance, and also provides a highly
effective treatment for hyperparasitemic patients and recrudescent
infections (Nosten et al., 1994, 2000; Luxemburguer et al., 1995;
Price et al., 1995).
The combination of artesunate and amodiaquine is an ACT
(artemisinin-based combination therapy) recommended by the
World Health Organization (WHO) for use in malaria control
programs, and is a ﬁrst-line treatment for African children with
non-complicated malaria (WHO, 2004).
Considering the use of artesunate in the treatment ofmalaria and
the inexistence of in vivo mammal cell studies investigating its ge-
netic toxicity, the main objective of this study was to evaluate the
genotoxic/mutagenic potential of artesunate in the peripheral blood
cells, liver and bone marrow of male albino (Mus musculus) Swiss
mice, using the comet assay (SCGE) and the micronucleus test.2. Materials and methods
2.1. Artesunate
Dihydroartemisinin was prepared from artemisinin using a routine procedure
(Brossi et al., 1988). The acid chloride RCOCl was prepared from the corresponding
carboxylic acids by heating them with thionyl chloride at 50–60 C for 2–3 h and
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dichloromethane at 0 C for 2 h to furnish ester derivatives in 49–58% yields.
Artesunate was prepared from dihydroartemisinin (DHA) by reacting it with succi-
nic acid anhydride in basic medium. Pyridine was used as a solvent, sodium bicar-
bonate as a base and DMAP (N,N-dimethylaminopyridine) and triethylamine in 1,2-
dichloroethane were used as catalysts, with yields of up to 100%. The mixture was
stirred up to 9 h to obtain artesunate in quantitative yield. The product was further
re-crystallized from dichloromethane. Alpha-Artesunate was exclusively formed
(m.p. 135–137 C).
2.2. Chemicals
Doxorubicin (DXR, Oncodox, Meizler) was used as the DNA damaging agent in
the comet and micronucleus assays, and was prepared by dissolving in sterile
water. The other main chemicals were obtained from the following suppliers: nor-
mal melting point (NMP) agarose (Cat. No. 15510–019: Invitrogen) low melting
point (LMP) agarose (Cat. No. 15517–014: Invitrogen), sodium salt N-lauroyl sarco-
sine (L-5125: Sigma) and ethylenediaminetetraacetic acid (EDTA) (Merck).
2.3. Animals and dosing
Experiments were carried out on 12-week old male Swiss albino mice (Mus
musculus), weighing 25–30 g. The animals were acquired from the animal house
of the Universidade Estadual Paulista (UNESP), Botucatu, São Paulo, Brazil and kept
in polyethylene boxes (n = 6) in a climate-controlled environment (25 ± 4 C,
55 ± 5% humidity) with a 12 h light/dark cycle (7 a.m.–7 p.m.). Food (NUVILAB
CR1 – NUVITAL) and water were available ad libitum. The mice were divided into
experimental groups of six animals/box. Artesunate was diluted in water and
administered in a single dose of 0.5 mL by gavage at concentrations of 5, 50 and
100 mg/kg body weight. These concentrations were based on our acute toxicity
studies in mice, as well as on studies of its antimalarial effects (Angus et al.,
2002). The negative control group received distilled water. The positive control
group received an intraperitoneal injection of Doxorubicin 80 mg/kg. The animals
used in this study were sacriﬁced by cervical dislocation. The experimental design
is presented in Table 1. The Animal Bioethics Committee of FAMEMA, Marília, Bra-
zil, approved this study on July 30, 2009 (protocol number 140/09), in accordance
with federal government legislation on animal care.
2.4. comet assay
The comet assay (SCGE) was carried out according to the method described by
Speit and Hartmann (1999), which is based on the original work of Singh et al.
(1988), and the guidelines discussed by Tice et al. (2000), as well as additional mod-
iﬁcations. Twenty-four hours after the treatment, peripheral blood leukocytes and li-
ver cells from six Swiss mice from each group were sampled. Liver samples were
washed in saline solution, in an ice bath. A small portion was transferred to a Petri
dish containing 1 mL of Hank’s solution (pH 7.5) and then homogenized gently with
small pinches. A 10-lL aliquot of cells from each animal was mixed with 120 lL of
0.5% low melting point agarose at 37 C, and immediately spread on microscope
slides pre-coated with 1.5% normal melting point agarose. Coverslips were added
and the slides were allowed to gel at 4 C for 20 min. The coverslips were gently re-
moved and the slides were then immersed in cold, freshly prepared lysing solution
consisting of 89 mL of a stock solution (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, pH
set to 10.0 with8 g solid NaOH, 890 mL of distilled water and 1% sodium lauryl sar-
cosine), plus 1 mL of Triton X-100 (Merck) and 10 mL of dimethylsulfoxid (Merck).
The slides, whichwere protected from light, were kept at 4 C for 1 h and then placed
in the gel box, positioned at the anode end, and immersed in a high pH (>13) electro-
phoresis buffer (300 mM NaOH per 1 mM EDTA, prepared from a stock solution of
10 N NaOH and 200 mM, pH 10.0, EDTA) at 4 C for 20 min prior to electrophoresis
in order to allow the DNA to unwind. The electrophoresis run was carried out in an
ice bath (4 C) for 20 min at 300 mA and 25 V (0.722 V cm1). The slides were then
submerged in a neutralization buffer (0.4 M Tris–HCl, pH 7.5) for 15 min, dried at
room temperature and ﬁxed in 100% ethyl alcohol for 10 min. The slides were dried
and stored overnight or longer before staining. For the staining process, each slide
was brieﬂy rinsed in distilled water, covered with 30 lL of 1 ethidium bromide
staining solution prepared from a 10 stock (200 lg/ml) and covered with a cover-
slip. Thematerial was evaluated immediately at 400magniﬁcation, using a ﬂuores-
cencemicroscope (Olympus BX50)with a 515–560 nmexcitation ﬁlter and a 590 nm
barrier ﬁlter.
The extent anddistribution ofDNAdamage indicated by the SCGE assaywas eval-
uated by examining at least 100 randomly selected and non-overlapping cells (50
cells per coded slide) per animal in a blind analysis (six mice per group). These cells
were scored visually, according to tail size, into the following four classes: class 0 –
no tail; class 1 – tail shorter than the diameter of the head (nucleus); class 2 – tail
length 1–2 times the diameter of the head; and class 3 – tail length more than twice
the diameter of the head. Comets with no heads, with nearly all of the DNA in the tail
or with a very wide tail were excluded from the evaluation because they probably
represented dead cells (Hartmann and Speit, 1997). The total score for 100 comets,
which ranged from 0 (all undamaged) to 300 (all maximally damaged), was obtained
by multiplying the number of cells in each class by the damage class.2.5. Micronucleus assay
The assay was carried out following standard protocols, as recommended by
Schmid (1975) and Krishna and Hayashi (2000). The same six mice per group used
in the comet assay were used in the micronucleus test. Animals were sacriﬁced 24 h
after the treatment. The bone marrow from both femurs was ﬂushed out using 2 mL
of saline solution (NaCl 0.9%) and centrifuged for 7 min. The supernatant was dis-
carded and smears were made. The slides were coded for a ‘‘blind’’ analysis, ﬁxed
with methanol and stained with Giemsa solution. For the micronucleated cell anal-
ysis, 2000 polychromatic erythrocytes (PCE) per animal were scored to determine
the mutagenic effects of artesunate. To detect possible cytotoxic effects, the PCE/
NCE (polychromatic/normochromatic erythrocyte) ratio from 200 erythrocytes/ani-
mal was calculated (Gollapudi and McFadden, 1995). Coded slides were scored with
a light microscope at 1000 magniﬁcation. The mean number of micronucleated
polychromatic erythrocytes (MNPCE) in individual mice was used as the experi-
mental unit, with variability (standard deviation) based on intragroup differences
among animals.
2.6. Statistical analysis
After verifying for normal distribution, the data obtained from micronucleus
and SCGE assays were submitted to one-way analysis of variance (ANOVA) and
the Tukey–Kramer multiple comparison test (Sokal and Rohlf, 1995) with the
GraphPad Instat software (version 3.01). The results were considered statistically
signiﬁcant at P < 0.05.
3. Results
The comet assay results are shown in Tables 1 and 2, where the
animals results for the different doses of artesunate and DXR-posi-
tive control are compared with the negative control (water). As ex-
pected, when the positive control was compared with the negative
control, we found that DXR induced a signiﬁcant increase
(P < 0.001 or greater) in comet assay DNA migration for leukocyte
and liver cells (Tables 1 and 2). We found a signiﬁcant increase
in DNAmigration only at a 5 and 50 mg/kg dose in liver cells. There
was no statistical difference in DNA migration between the three
tested doses of artesunate. At the dosage that induced a signiﬁcant
increase in DNA damage in liver cells cells, most of the damage was
minor (class 1), with only a very few cells showing a large amount
of damage (classes 2 and 3).
Table 3 shows the micronucleus test results obtained for male
Swiss mice treated with artesunate: the mean number of micronu-
cleated polychromatic erythrocytes (MNPCE) in untreated controls
and treatedanimals.As expected, thepositivemutagenDXR induced
a statistically signiﬁcant increase in MNPCE. The clastogenicity test
revealed an increase in the mean number of MNPCE at all tested
doses, being statistically signiﬁcant at the twohighest doses. Theob-
served clastogenicity was dose-related. The tested substance no
caused a statistically signiﬁcant decrease in PCE/NCE ratios. These
data suggest that artesunate had a weak clastogenic effect on the
bone marrow cells of mice without cytotoxic effects.
4. Discussion
Before the approval of new pharmaceutical products, either nat-
ural or synthetic, both their therapeutic and their toxicological ef-
fects must be evaluated, so that only substances free from potential
mutagenic effects are introduced (Rodeiro et al., 2006). Several
studies have suggested that mutagenic agents produce carcino-
genic effects (Chandra et al., 2006). The combined use of the comet
Assay and micronucleus test in a single study has yielded good
results. Vasquez (2010), using the damage-inducing agents Mito-
mycin C and Cyclophosphamide, tested both techniques concomi-
tantly on different tissues of rats and mice, and thus reduced the
number of animals used without compromising the efﬁcacy of
the test.
Through the comet assay, it is possible to quantify and distin-
guish different DNA damage levels, seeing that the evaluation of
scores for each experimental group is highly important. In this
Table 1
DNA migration in the comet assay for the assessment of genotoxicity of artesunate in peripheral blood cells (collected 24 h after the treatment)
from Swiss mice male (M) in vivo.
Treatments Animals Totala Comet class Scores
0 1 2 3
Control M1 11 89 11 0 0 11
M2 9 91 9 0 0 9
M3 8 92 8 0 0 8
M4 9 91 9 0 0 9
M5 11 89 11 0 0 11
M6 12 88 12 0 0 12
Mean ± SD 10.0 ± 1.54 10.0 ± 1.54
Artesunate (5 mg/kg) M1 1 99 1 0 0 1
M2 3 97 3 0 0 3
M3 6 94 6 0 0 6
M4 8 92 7 1 0 9
M5 4 96 4 0 0 4
M6 6 94 6 0 0 6
Mean ± SD 4.66 ± 2.50 4.83 ± 2.78
Artesunate (50 mg/kg) M1 5 95 4 1 0 6
M2 6 94 4 2 0 8
M3 4 96 3 1 0 5
M4 1 99 1 0 0 1
M5 4 96 4 0 0 4
M6 2 98 2 0 0 2
Mean ± SD 3.66 ± 1.86 4.33 ± 2.58
Artesunate (100 mg/kg) M1 5 94 3 2 0 7
M2 2 98 2 0 0 2
M3 5 95 4 1 0 6
M4 4 96 4 0 0 4
M5 1 99 1 0 0 1
M6 3 97 3 0 0 3
Mean ± SD 3.33 ± 1.63 3.83 ± 2.31
Doxorubicin (80 mg/kg) M1 97 3 36 39 22 180
M2 98 2 42 40 16 170
M3 98 2 33 34 31 194
M4 100 0 45 35 20 175
M5 100 0 48 44 8 160
M6 100 0 51 32 17 166
Mean ± SD 98.8 ± 1.32* 174.1 ± 11.9*
* Signiﬁcantly different from the negative control (P < 0.001).
a Total number of cells with damage (class 1 + 2 + 3).
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cells of animals. To the tree tested doses the observed DNA damage
was signiﬁcantly lower than that observed in the negative control
group. On the other hand, in liver cells, the 5 mg/kg and 50 mg/kg
doses were genotoxic; the 100 mg/kg dose also increased the total
number of damaged cells, but this increase was not statistically
signiﬁcant. Among the damaged nucleoids, class 1 comets were
predominant. However, in the group treated with doxorubicin,
class 2 and 3 comets predominated. Thus, low doses of artesunate
were sufﬁcient to produce low genotoxicity in liver cells.
Li et al. (2008) analyzed CHO-9 (Chinese hamster ovary cell
line) cells and V79-2 (hamster lung ﬁbroblast cell line) cells with
the comet assay and veriﬁed that, in vitro, artesunate induced
DNA damage and apoptosis. These authors also concluded that,
in mammal cells, artesunate generated damage through direct or
indirect oxidative stress, resulting in DNA strand breakage. The
present study conﬁrms such genotoxicity in vivo and if the
generation of reactive oxygen species could be involved in the
genotoxicity of artesunate need further studies.
Damage to the DNA molecule, such as adducts and breakage of
single or double strands, could become permanent lesions, and the
micronucleus test is an excellent means of investigating this type
of damage in genetic material (Serpeloni et al., 2008). Furthermore,
the micronucleus test can detect cytotoxic effects by the analysis of
the PCE/NCE ratio. When the normal proliferation of bone marrow
cells is affected by a cytotoxic agent, there is a reduction in the
number of immature erythrocytes (PCE) compared to the numberof mature erythrocytes (NCE), thus reducing the PCE/NCE ratio
(Gollapudi and McFadden, 1995). The PCE/NCE ratios observed in
bone marrow cells were not different that observed in control
group, indicating that the tested compound no affected the normal
proliferation of erythrocytes in bone marrow, which represents a
no cytotoxic effect.
The frequency of micronucleated cells was analyzed after 24 h
of treatment (Krishna and Hayashi, 2000). The results indicated
that the positive control (Doxorubicin) caused a signiﬁcant in-
crease (P < 0.001) in the number of micronucleated cells compared
to the negative control, thus conﬁrming the sensitivity of the test.
In the groups treated with artesunate at doses of 50 and 100 mg/
kg, there was a statistically signiﬁcant increase in micronucleated
polychromatic erythrocytes compared to control (P < 0.001). This
means that, under our experimental conditions, artesunate
presented clastogenic/aneugenic activity at the two highest doses
tested.
Antineoplastic drugs are cytotoxic, and some studies suggest
that the cytotoxic activity of artesunate may be effective against
cancer by causing damage to cancer cells, delaying the cellular cy-
cle, inhibiting the proliferation of solid tumors, or even inducing
apoptosis (Efferth et al., 2003, 2007; Hou et al., 2008; Chen et al.,
2010; Du et al., 2010; Cai et al., 2011). Nevertheless, it is necessary
to rigorously investigate their safety, given that artesunate pre-
sented genotoxic and clastogenic/aneugenic activity in the present
study, which might invalidate its use for treating both malaria and
cancer.
Table 2
DNA migration in the comet assay for the assessment of genotoxicity of artesunate in liver cells (collected 24 h after the treatment) from Swiss mice male (M) in vivo.
Treatments Animals Totala Comet class Scores
0 1 2 3
Control M1 6 94 6 0 0 6
M2 9 91 9 0 0 9
M3 9 91 8 1 0 10
M4 10 90 9 1 0 11
M5 7 93 5 2 0 9
M6 4 96 4 0 0 4
Mean ± SD 7.5 ± 2.25 8.16 ± 2.63
Artesunate (5 mg/kg) M1 16 84 16 0 0 16
M2 18 82 16 2 0 20
M3 21 79 21 0 0 21
M4 17 83 17 0 0 17
M5 17 83 12 5 0 22
M6 16 84 16 0 0 16
Mean ± SD 17.5 ± 1.87*** 18.6 ± 2.65**
Artesunate (50 mg/kg) M1 8 92 8 0 0 8
M2 18 82 18 0 0 18
M3 11 89 11 0 0 11
M4 16 84 16 0 0 16
M5 17 83 17 0 0 17
M6 15 85 13 2 0 17
Mean ± SD 14.1 ± 3.86* 14.5 ± 4.03
Artesunate (100 mg/kg) M1 9 91 9 0 0 9
M2 6 94 6 0 0 6
M3 20 80 18 2 0 22
M4 11 89 6 5 0 16
M5 7 93 7 0 0 7
M6 16 84 14 2 0 18
Mean ± SD 11.5 ± 5.46 13.0 ± 6.57
Doxorubicin (80 mg/kg) M1 96 4 42 39 15 165
M2 98 2 43 38 15 164
M3 96 4 45 39 12 159
M4 97 3 46 34 17 165
M5 95 5 42 32 21 169
M6 98 2 43 38 17 170
Mean ± SD 96.6 ± 1.21*** 165.3 ± 3.93***
* Signiﬁcantly different from the negative control (P < 0.05).
** Signiﬁcantly different from the negative control (P < 0.01).
*** Signiﬁcantly different from the negative control (P < 0.001).
a Total number of cells with damage (class 1 + 2 + 3).
Table 3
Number of micronucleated polychromatic erythrocytes (MNPCE) observed in the bone marrow cells of male (M) Swiss mice treated with artesunate, and respective controls. Two
thousand cells were analyzed. SDM = standard deviation of the mean.
Treatments Number of MNPCE per animal MNPCE Mean ± SD PCE/NCE Mean ± SD
M1 M2 M3 M4 M5 M6
Negative control (water) 3 3 3 2 2 1 2.33 ± 0.81 1.10 ± 0.02
Artesunate (5 mg/kg) 2 1 3 4 3 3 2.66 ± 1.03 1.07 ± 0.03
Artesunate (50 mg/kg) 8 5 4 5 8 7 6.16 ± 1.72* 1.08 ± 0.03
Artesunate (100 mg/kg) 6 8 9 7 6 9 7.5 ± 1.37* 1.1 ± 0.04
Doxorubicin (80 mg/kg) 83 83 82 83 81 82 82.3 ± 0.81* 0.98 ± 0.04*
* Signiﬁcantly different from negative control (P < 0.001).
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cytotoxic effects but at the higher tested doses, induced clasto-
genic/aneugenic activity in young bone marrow erythrocytes.
And although artesunate no induced DNA damage in cells that do
not metabolize as a peripheral blood, at high doses it caused
DNA damage in cells that do, such as those in the liver.Conﬂict of Interest
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